SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-23-000026
Filing Date
2023-05-05
Accepted
2023-05-05 10:13:50
Documents
7
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 6-K q12023form6-k.htm 6-K 22546
2 EX-99.1 2023 FIRST QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsmarch312023.htm EX-99.1 304454
3 EX-99.2 2023 FIRST QUARTER MD&A ex992-q12023mda.htm EX-99.2 180741
4 EX-99.3 Q3 2023 CERTIFICATION CEO ex993-q12023certificationx.htm EX-99.3 14481
5 EX-99.4 Q3 2023 CERTIFICATION CFO ex994-q12023certificationx.htm EX-99.4 14378
6 mdapipelinea.jpg GRAPHIC 520833
7 oncolyticslogotaglineblueaa.jpg GRAPHIC 355294
  Complete submission text file 0001129928-23-000026.txt   1694056
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 23891819
SIC: 2834 Pharmaceutical Preparations